Abstract
The ENHANCE study will assess the effect of ezetimibe plus simvastatin in patients with heterozygous familial hypercholesterolaemia. Carotid artery intima-media thickness will be measured, which is able to predict a progression to cardiovascular or cerebrovascular events.
The SEAS study will evaluate whether treatment with ezetimibe and simvastatin, compared with placebo, will reduce the risk of major cardiovascular events in patients with aortic stenosis.
The SHARP study will measure major vascular events in patients with chronic kidney disease or who are receiving dialysis. Ezetimibe and simvastatin treatment will be compared with placebo.
Get full access to this article
View all access options for this article.